Atrial fibrillation (AFib) affects millions of people in high-income countries, and the standard of care for stroke prevention—anticoagulation with direct oral anticoagulants (DOACs)—is reliably prescribed to eligible patients. Yet a second, potentially more definitive intervention, catheter ablation, remains unevenly accessible. In some regions, patients can see an electrophysiologist within weeks; in others, they may never be offered the option. This postcode-based lottery for advanced care raises questions about equity, evidence, and how health systems decide which treatments to prioritize.

Anticoagulants Are Standard, but Ablation Access Is Not

Guidelines from cardiology societies across the US, Europe, and Japan recommend anticoagulation for AFib patients with a CHA₂DS₂-VASc score of 2 or higher in men and 3 or higher in women. DOACs—such as apixaban, rivaroxaban, and edoxaban—are now prescribed to the vast majority of these patients. Observational data from the US Medicare population suggest that roughly 80% of eligible beneficiaries receive an anticoagulant within a year of diagnosis.

Catheter ablation, by contrast, is offered to a far smaller subset. The procedure involves threading a catheter through the femoral vein to the heart, where radiofrequency energy or cryoenergy is used to isolate the pulmonary veins and eliminate the abnormal electrical signals driving AFib. Randomized trials, including the CASTLE-AF study, have shown that ablation reduces hospitalization for heart failure and, in some analyses, all-cause mortality among patients with AFib and heart failure with reduced ejection fraction.

Despite this evidence, ablation rates vary dramatically by region. In the UK, the National Audit of Cardiac Rhythm Management reported that in 2023, the rate of ablation per 100,000 population was roughly three times higher in London than in some rural areas of the North East. In the United States, Medicare claims data show that patients in the Northeast and West are more likely to undergo ablation than those in the South or Midwest, even after adjusting for age, sex, and comorbidity burden.

The gap is not simply a matter of patient preference. Many patients are never referred to an electrophysiologist, and primary care clinicians may not be aware of the potential benefits of ablation for certain subgroups. As a result, the decision to offer ablation often depends less on clinical need and more on where a person lives.

Where You Live Shapes Whether You Get Catheter Ablation

The pattern of geographic variation is remarkably consistent across high-income countries. In the UK, the 2023 audit found that ablation rates in the South West were roughly half those in London. In Australia, data from the Australian Institute of Health and Welfare show that patients in major cities are about twice as likely to undergo ablation as those in remote areas. In Japan, the density of electrophysiology centers in Tokyo and Osaka means that urban patients can access high-volume operators, while rural patients may need to travel several hundred kilometers.

In the United States, a 2022 analysis of Medicare fee-for-service beneficiaries found that the rate of ablation per 1,000 AFib patients ranged from about 15 in parts of Mississippi to over 40 in parts of Massachusetts. The authors noted that the variation was not explained by differences in patient age, race, or comorbidity. Instead, it correlated with the local supply of electrophysiologists.

Travel burden is a real barrier. For a patient in rural Montana, a referral to an electrophysiologist may mean a 400-mile round trip. For an elderly patient without reliable transportation, that distance can be prohibitive. Some patients forgo ablation entirely, or they receive it only after their AFib has progressed to a more advanced stage, when the procedure may be less effective.

The consequences of this variation are not merely academic. AFib is associated with a fivefold increase in stroke risk, and while anticoagulation reduces that risk substantially, it does not eliminate it. Ablation can reduce stroke risk in selected patients, particularly those with paroxysmal AFib and few comorbidities. When ablation is inaccessible, those patients may continue to experience symptoms and face a higher long-term risk of stroke.

The Evidence Gap: Ablation vs. Drugs in Real-World Populations

The randomized trials that support ablation were conducted in carefully selected populations. The CASTLE-AF trial, for instance, enrolled patients with paroxysmal or persistent AFib and heart failure with a left ventricular ejection fraction of 35% or less. The median age was 64 years, and the patients were relatively healthy aside from their heart condition. The trial showed a 38% reduction in the primary endpoint of death or hospitalization for heart failure.

But the typical AFib patient in the community is older and has more comorbidities. The median age of AFib patients in the US Medicare population is around 77 years. Many have hypertension, diabetes, chronic kidney disease, or a history of stroke. These patients were underrepresented in the pivotal trials, and the evidence for ablation in this group is less robust.

Observational studies have attempted to fill the gap. A 2023 analysis of the Swedish National Patient Register found that among patients aged 75 and older, ablation was associated with a lower risk of stroke and death compared with medical therapy alone, but the absolute risk reduction was smaller than in younger patients. The authors cautioned that residual confounding could explain some of the benefit.

This uncertainty fuels disagreement among experts. Some interventional cardiologists argue that the trial evidence is strong enough to justify expanding access to all eligible patients. Electrophysiologists, who perform the procedure, often cite recurrence rates of 20–30% within a year and the risk of complications, including cardiac tamponade, stroke, and esophageal injury. Primary care clinicians, who are the gatekeepers to specialist referral, may be unsure which patients are most likely to benefit.

Why Experts Disagree on Expanding Ablation Access

The debate over expanding ablation access is not simply about resources; it is about how to interpret the available evidence. Interventional cardiologists point to data from the CABANA trial, which showed a reduction in the composite endpoint of death, stroke, and hospitalization with ablation, though the difference was not statistically significant in the intention-to-treat analysis. A per-protocol analysis, however, suggested a significant benefit.

Electrophysiologists counter that the procedure carries a non-negligible risk. A 2024 review in the Journal of Cardiovascular Electrophysiology reported a major complication rate of roughly 4% in contemporary practice, with tamponade occurring in about 1% of cases. They argue that ablation should be reserved for patients who have failed or cannot tolerate antiarrhythmic drugs, as recommended by current guidelines.

Health economists have weighed in with cost-effectiveness analyses. A 2023 study from the UK estimated that ablation is cost-effective at a threshold of £20,000 per quality-adjusted life year (QALY) for patients with symptomatic paroxysmal AFib who have failed one antiarrhythmic drug. But for older, frailer patients, the incremental cost per QALY may exceed £50,000, making it less attractive from a societal perspective.

Society guidelines reflect this ambivalence. The 2024 European Society of Cardiology guidelines give a class I recommendation for ablation in patients with paroxysmal AFib who have failed a trial of antiarrhythmic drugs, but a class IIa recommendation for first-line therapy in selected patients. The American Heart Association guidelines similarly condition the recommendation on patient characteristics and operator expertise. These conditional recommendations leave room for wide variation in practice.

Structural Barriers Beyond Distance and Density

Even when patients live near a center that offers ablation, other barriers can prevent access. Low awareness among referring doctors is a major factor. A 2022 survey of primary care physicians in the United States found that only about half were aware that ablation could reduce stroke risk in AFib patients with heart failure. Many still viewed ablation as a last resort for symptom control only.

The shortage of electrophysiology-trained operators is another constraint. In the United States, there are roughly 1,500 board-certified electrophysiologists, and most practice in urban areas. Training programs produce only about 80 new electrophysiologists per year, which is insufficient to meet growing demand. In the UK, the number of electrophysiologists per capita is roughly half that of the United States.

Reimbursement models can also discourage ablation. In some US insurance plans, step therapy protocols require patients to try one or two antiarrhythmic drugs before ablation is covered. This can delay the procedure by months or years, during which time the patient's AFib may progress from paroxysmal to persistent, making ablation less effective. A related issue is the prior authorization process, which has been shown to delay chemotherapy in oncology; a similar dynamic can affect cardiac procedures.

Healthcare systems in many high-income countries prioritize acute care over elective services. Ablation is often categorized as elective, even though it can prevent future strokes. During the COVID-19 pandemic, elective procedures were deferred, and in some regions, ablation volumes have not fully recovered. The backlog disproportionately affects patients in underserved areas.

Closing the Gap: What Could Make Access More Equitable

Several strategies have been proposed to reduce geographic disparities in ablation access. Telemedicine offers a low-cost way to expand the reach of electrophysiology expertise. Remote pre-ablation screening, where a local clinician performs an initial evaluation and then discusses the case with a specialist via video link, can identify candidates who are likely to benefit. Pilot programs in rural Scotland and Australia have shown that this approach can reduce travel burden and increase referral rates.

Mobile ablation units—essentially, a catheterization laboratory on wheels—have been piloted in rural Australia. These units travel to remote communities, perform ablations over a few days, and then move on. A 2024 report from the Royal Australian College of General Practitioners described the model as feasible and well-received by patients, though the cost per procedure was higher than in fixed centers.

Training programs to increase the electrophysiology workforce outside major cities are another avenue. In the United States, some academic centers have established satellite fellowships that allow trainees to spend part of their training in rural hospitals. In Japan, the government has funded the creation of regional heart centers with dedicated electrophysiology labs. These efforts take time to produce results, but they address the root cause of the shortage.

Risk-stratification tools could help identify which patients are most likely to benefit from ablation, allowing resources to be targeted to those with the highest net benefit. The APPLE score, for example, combines age, persistent AFib, estimated glomerular filtration rate, and left atrial diameter to predict recurrence after ablation. Using such tools could reduce the number of patients who undergo a procedure with little chance of success, improving cost-effectiveness.

Policy changes to fund travel or local centers have been implemented in some regions. In New Zealand, the health ministry funds travel and accommodation for patients who need to travel more than 100 kilometers for specialist care. In Canada, some provinces have established centralized referral networks that triage patients to the nearest available electrophysiology center. These initiatives reduce the financial burden on patients and may improve equity.

For Patients: Questions to Ask When Ablation Isn't Offered

For patients with AFib who are not offered ablation, there are several questions worth discussing with their healthcare provider. First, what is their CHA₂DS₂-VASc score and estimated stroke risk? This helps clarify the potential benefit of anticoagulation and whether additional interventions might be warranted.

Second, have symptoms persisted despite rate control or rhythm control with medications? If a patient is symptomatic—experiencing palpitations, shortness of breath, or fatigue—ablation may improve quality of life even if the stroke risk is already managed with anticoagulation.

Third, is an electrophysiology consult available via telehealth? Many centers now offer remote consultations, which can provide a second opinion without the need for travel. Patients can ask their primary care clinician for a referral.

Fourth, are there clinical trials or regional referral networks that could provide access? Some large academic centers participate in registries that offer ablation at reduced cost or through research protocols. Patients can search for trials at ClinicalTrials.gov or ask their local hospital.

Finally, shared decision-making requires knowing the options. A patient who understands the rationale for ablation, its risks, and its potential benefits is better equipped to advocate for themselves if the procedure seems appropriate. A 2023 systematic review found that patients who received decision aids were more likely to choose ablation when it was clinically indicated and had higher satisfaction with their care.

Disclaimer: This article is for informational purposes only and does not constitute personalized medical advice. Patients should consult their healthcare provider to discuss their individual risk factors and treatment options.